Drugs / VRC-FLUNPF099-00-VP (H1ssF_3928)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05755620 | Apr 2023 → Oct 2025 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-FLUNPF099-00-VP (H1ssF_3928) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05755620 ↗ |
| Known as | H1ssF 3928 | “This study is designed to assess the safety and immunogenicity of one dose of H1ssF 3928 mRNA Vaccine.” NCT05755620 ↗ |
| Modality | Messenger RNA (mRNA) | “The vaccine consists of modified nucleoside messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP)” NCT05755620 ↗ |
| Route | Intramuscular | “intramuscularly (IM) administered mRNA-LNP vaccine” NCT05755620 ↗ |